Cover My Eyes (Pain and Heaven)

Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference

Retrieved on: 
Thursday, June 2, 2022
Health, Diabetes, Managed Care, General Health, Clinical Trials, Pharmaceutical, Optical, ENDO, Atlantic Station, Conference, Insomnia, National Track and Field Hall of Fame, Autoantibody, 2013 British National Track Championships, Weight loss, Inflammation, Irritation, Gold, Courage, Swelling, Convention, Endocrine system, Blood, Graves' ophthalmopathy, Diagnosis, Autoimmunity, National Primate Research Exhibition Hall, American Association of Clinical Endocrinologists, Patient, Career, Communications center, Cell, Translation, Exophthalmos, Fibroblast, University, Dry, Michigan Medicine, Teprotumumab, Gail Devers, Science, Health, Education, Fatigue, Strabismus, LinkedIn, TED, NorthShore University HealthSystem, Disease, Nasdaq, Lists of World Heritage Sites, Division, Twitter, Diplopia, Cover My Eyes (Pain and Heaven), Instagram, European Group, Pharmaceutical industry, Veterinary medicine, Olympian, Endocrinology, Facebook

ET in ENDOExpo Theater 1, titled Evolution of Thyroid Eye Disease (TED) Treatment With Teprotumumab: Translating Bench to Bedside with Terry J. Smith, M.D., Michigan Medicine Eye Plastic, Facial Cosmetic & Orbital Surgery, Kellogg Eye Center, University of Michigan Medical School.

Key Points: 
  • ET in ENDOExpo Theater 1, titled Evolution of Thyroid Eye Disease (TED) Treatment With Teprotumumab: Translating Bench to Bedside with Terry J. Smith, M.D., Michigan Medicine Eye Plastic, Facial Cosmetic & Orbital Surgery, Kellogg Eye Center, University of Michigan Medical School.
  • The event, Achieving Gold in the Co-Management of Thyroid Eye Disease (TED), will be held in The Career and Communications Center in the Exhibit Hall on Saturday, June 11 at 11 a.m.
  • Gail will also be sharing her story between 11 a.m. and 4 p.m.
  • After a harrowing two-and-a-half-year quest for answers, she was diagnosed with Graves disease in 1990, just two years before winning her first Olympic gold medal.

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Retrieved on: 
Monday, May 23, 2022
Medicine, Food, Mycosis, U.S. Securities and Exchange Commission, NCE, Infection, KALA, Visual acuity, MPP, Duane syndrome, IOP, Loteprednol, Private Securities Litigation Reform Act, Steroid, Ophthalmology, Wilmer Cutler Pickering Hale and Dorr, Tissue, Pain, Degenerative disease, Incidence, COVID-19, Marketing, Food and Drug Administration, Chickenpox, Cover My Eyes (Pain and Heaven), GLOBE, Inflammation, Company, Coronavirus, Eye, Herpes simplex, FDA, Conjunctiva, Feed additive, Sclera, Adverse drug reaction, Cornea, Security (finance), Risk, History, Vaccinia, Patient, NASDAQ, LE, Technology, Slit lamp, Glaucoma, Sale, Hart–Scott–Rodino Antitrust Improvements Act, Optic nerve, Health insurance, Pharmaceutical industry, Vaccine, Alcon

ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. This includes EYSUVIS, the first and only U.S. Food and Drug Administration (FDA) approved medicine for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS, a twice-a-day corticosteroid for the treatment of post-operative inflammation and pain following ocular surgery.

Key Points: 
  • Kala plans to focus on developing KPI-012, a novel cell-free secretome therapy that has the potential to address a number of rare and severe ocular diseases.
  • Under the terms of the asset purchase agreement, Kala will receive an upfront payment of $60 million and will be eligible to receive commercial-based sales milestone payments.
  • Piper Sandler acted as the exclusive financial advisor, and Wilmer Cutler Pickering Hale and Dorr LLP served as legal counsel to Kala.
  • Kala believes INVELTYS has a favorable profile for the treatment of inflammation and pain following ocular surgery, due to its twice-a-day dosing regimen.

Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States

Retrieved on: 
Monday, May 2, 2022
Pharmaceutical, Health, Optical, Cytokine, Immune system, Pain, Inc., Eye, Vernal keratoconjunctivitis, Patient, Founder, Acquisition, OTC, Risk, FDA, Inflammation, Eye injury, Severe cognitive impairment, VKC, Ophthalmology, Quality of life, Uncertainty, Cornea, Tearing, Disease, Mark (given name), Achievement, Allergic inflammation, Cover My Eyes (Pain and Heaven), CEO, Research, Sport, Pharmaceutical industry, Ciclosporin

We are proud to make Verkazia available for all those with VKC in the United States who have lacked optimal treatment options for this condition.

Key Points: 
  • We are proud to make Verkazia available for all those with VKC in the United States who have lacked optimal treatment options for this condition.
  • In addition, having a treatment option for the rare disease VKC will strengthen our existing product portfolio for ocular surface disease in the United States.
  • Worldwide, Verkazia is available for the treatment of VKC in the United States, Canada, and select countries across Asia and Europe.
  • Verkazia (cyclosporine ophthalmic emulsion) 0.1% is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
Thursday, April 28, 2022
Medicine, U.S. Securities and Exchange Commission, LinkedIn, Retina, Headache, Lens (anatomy), Infection, Central retinal vein occlusion, YouTube, Twitter, Patient, AbbVie, FDA, Pilocarpine, Private Securities Litigation Reform Act, COVID-19, Cell, Gastroenterology, Risk, Glaucoma, Presbyopia, Epidemic, Cornea, Intraocular pressure, Cover My Eyes (Pain and Heaven), Allergy, Iris, Annual report, Acquisition, Security (finance), Eye, Failure, News, Research, Neuroscience, Diabetic retinopathy, Virology, Industry, IOP, Mark (given name), Ocular hypertension, Swelling, Instagram, Inflammation, Health, Pandemic, Telescopic sight, Cosmetics, Dietary supplement, Pharmaceutical industry, Camera, Allergan, Facebook

NORTH CHICAGO, Ill., April 28, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data on VUITY™ (pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia (age-related blurry near vision) in adults, and DURYSTA® (bimatoprost intracameral implant), a first-of-its-kind biodegradable implant to lower eye pressure for glaucoma patients, at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 1-4 in Denver, CO.

Key Points: 
  • VUITY is an optimized formulation of pilocarpine, an established eye care therapeutic, specifically designed to treat age-related blurry near vision.
  • VUITY uses the eye's own ability to reduce pupil size and improves near and intermediate vision without compromising distance vision.
  • VUITY(pilocarpine hydrochloride ophthalmic solution) 1.25% is aprescription eye drop used to treat age-related blurry near vision (presbyopia) in adults.
  • If more than one topical eye medication is being used, the medicines must be administered at least 5 minutes apart.

Neuromyelitis Optica Linked to Antibody Exposure During Fetal Development, Feinstein Institutes Study Finds

Retrieved on: 
Wednesday, April 20, 2022
Science, Women, Biotechnology, Research, Optical, Health, Baby, Maternity, Consumer, Diamond, Embryonic development, LinkedIn, Northwell Health, BBB, Medicine, Spectrum disorder, Paralysis, Woman, Science Translational Medicine, Feinstein Institute for Medical Research, Genetics, Autism, DRS, Research, Fetus, Medical research, MD, Transport, Diagnosis, Science, Human, CNS, Central nervous system, Brain, Paper, Molecular medicine, Doctor of Philosophy, Severe cognitive impairment, Autoimmune disease, Credit, Development, Mental health, Pregnancy, Feinstein, Autoimmunity, Mother, Neuromyelitis optica spectrum disorder, Multimedia, Antibody, Cover My Eyes (Pain and Heaven), Male, Disease, Weatherall Institute of Molecular Medicine, Health, Institute, Cancer, Vaccine, Medical imaging, NMOSD

Neuromyelitis optica spectrum disorders (NMOSD) are inflammatory diseases of the central nervous system (CNS) leading to eye pain, blindness and even paralysis.

Key Points: 
  • Neuromyelitis optica spectrum disorders (NMOSD) are inflammatory diseases of the central nervous system (CNS) leading to eye pain, blindness and even paralysis.
  • View the full release here: https://www.businesswire.com/news/home/20220420006046/en/
    Dr. Lior Brimberg is co-lead author on the study of the rare condition.
  • Recognizing the presence of this particular antibody may lead to an earlier diagnosis and treatment interventions to improve pregnancy outcomes.
  • The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State.

ValenzaBio Announces FDA Clearance of Investigational New Drug Application for VB421, an Anti-IGF-1R Monoclonal Antibody for the Treatment of Thyroid Eye Disease

Retrieved on: 
Thursday, March 31, 2022
FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Graves' ophthalmopathy, Company, Therapy, Autoimmunity, IND, PD, Diplopia, TED, Food, Inflammation, Neutralizing antibody, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Exophthalmos, Cover My Eyes (Pain and Heaven), FDA, Patient, Pharmaceutical industry, MD

ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced that its investigational new drug (IND) application for its lead drug candidate, VB421, for the treatment of thyroid eye disease (TED), has been cleared by the U.S. Food and Drug Administration (FDA) for clinical evaluation.

Key Points: 
  • ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced that its investigational new drug (IND) application for its lead drug candidate, VB421, for the treatment of thyroid eye disease (TED), has been cleared by the U.S. Food and Drug Administration (FDA) for clinical evaluation.
  • VB421 is a potential best-in-class mAb targeting IGF-1R, which plays a central role in the pathogenesis of TED.
  • VB421 binds to IGF-1R with sub-50 pM potency and possesses favorable biophysical properties that may provide a differentiated product profile relative to other anti-IGF-1R antibodies.
  • These advantages may enable a patient-friendly, rapid, and small-volume subcutaneous injection that could expand settings of care for TED patients.

BAD HABITS: OVER FIVE MILLION BRITS PUTTING THEIR EYE HEALTH AT RISK BY SKIPPING THIS ONE SIMPLE THING, GUIDE DOGS' SURVEY REVEALS

Retrieved on: 
Thursday, March 31, 2022
Risk, Family, The Guide Dogs for the Blind Association, Cataract, Parent, NEVER, Glaucoma, Severe cognitive impairment, Lens (anatomy), Sleep, Dog, Retina, Irritation, Pain, Habit, Oxygen, Cornea, Diabetes, Eye, Cover My Eyes (Pain and Heaven), Animal, Telescopic sight, Whitstable

That could mean around five million people are putting their eye health at risk by skipping these important check-ups.

Key Points: 
  • That could mean around five million people are putting their eye health at risk by skipping these important check-ups.
  • Laura Drew, 39, from Whitstable was diagnosed with a macular hole following an eye check-up at her local opticians.
  • The survey also reveals other seemingly harmless bad habits that could compromise eye health.
  • For more information on eye health and how to look after your eyes, visit Guide Dogs' eye conditions hub .

BAD HABITS: OVER FIVE MILLION BRITS PUTTING THEIR EYE HEALTH AT RISK BY SKIPPING THIS ONE SIMPLE THING, GUIDE DOGS' SURVEY REVEALS

Retrieved on: 
Thursday, March 31, 2022
Risk, Family, The Guide Dogs for the Blind Association, Cataract, Multimedia, Parent, NEVER, Glaucoma, Severe cognitive impairment, Lens (anatomy), Sleep, Dog, Retina, Irritation, Pain, Habit, Oxygen, Cornea, Diabetes, Eye, Cover My Eyes (Pain and Heaven), Animal, Telescopic sight, Personal protective equipment, Whitstable

That could mean around five million people are putting their eye health at risk by skipping these important check-ups.

Key Points: 
  • That could mean around five million people are putting their eye health at risk by skipping these important check-ups.
  • Laura Drew, 39, from Whitstable was diagnosed with a macular hole following an eye check-up at her local opticians.
  • The survey also reveals other seemingly harmless bad habits that could compromise eye health.
  • For more information on eye health and how to look after your eyes, visit Guide Dogs' eye conditions hub .

Genentech to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting

Retrieved on: 
Friday, March 25, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Birth, Risk, Hepatitis B virus, Cancer, Rash, SMN2, Shingles, Liver failure, Vaccination, Death, Simplex, SMA, Spinal muscular atrophy, Disability, Fertility, Confusion, Adult, Skin, Central nervous system, Vaccine, CNS, Pregnancy, Pachydactylus labialis, Fever, Antibody, Focal neurologic signs, Patient, Infection, Health, Medicine, Thought, Pain, Breast milk, Immune system, Mouth, PML, Vitamin, Progressive multifocal leukoencephalopathy, MS, Hepatitis B, Encephalitis, Protein, Male, Pharmacy, Chills, Weakness, Neuron, Movement, HBV, SMN, Liver, Cover My Eyes (Pain and Heaven), FDA, Breast cancer, Water, Medical device, Health insurance, Birth control, Dietary supplement, Risk management, Pharmaceutical industry, Ocrelizumab, Risdiplam, Risdiplam, OCREVUS® (OCRELIZUMAB), EVRYSDI™ (RISDIPLAM), ENSPRYNGTM (SATRALIZUMAB), ENSPRYNGTM, GENENTECH IN NEUROSCIENCE, GENENTECH

If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

Key Points: 
  • If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
  • Signs of infection can happen during treatment or after you have received your last dose of Ocrevus.
  • Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with Ocrevus treatment in clinical trials, PML may happen with Ocrevus.
  • Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms.

Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting

Retrieved on: 
Thursday, February 24, 2022
Eye, Risk, Cell, Failure, Intraocular pressure, Security (finance), Use, Virology, Iris, Private Securities Litigation Reform Act, Research, Headache, Gastroenterology, Drainage, IOP, Glaucoma, Inflammation, Aqueous humour, Sclera, Pseudoexfoliation syndrome, Sale, Safety, U.S. Securities and Exchange Commission, Diabetic retinopathy, Blood, YouTube, Ocular hypertension, Twitter, Neuroscience, Central retinal vein occlusion, Evolutionary anachronism, Swelling, LinkedIn, Allergan, Choroid, Instagram, Patient, AbbVie, Health, Cornea, Eyelid, Retina, Annual report, Stent, Industry, Conjunctiva, Scar, Acquisition, Finger, News, Uvea, Cover My Eyes (Pain and Heaven), Infection, SEC, Pharmaceutical industry, Telescopic sight, Camera, Dentistry, Facebook

DURYSTA should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.

Key Points: 
  • DURYSTA should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.
  • DURYSTA should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).
  • DURYSTA may cause swelling of the macula, the center spot of the retina (back of the eye).
  • Eye injections have been associated with infections in the eye.